Solana Co Q3 FY2023 earnings call

• Concluded the successful Patient Therapy Access Program (PTAP) in June 2022, which reduced a major barrier to PoNS use and added to the MS patient registry. - Received UPC numbers for PoNS system and mouthpiece, with PoNS now having 2 paths to reimbursement due to DME accreditation. - Established relationships with Canadian healthcare providers, including an order from the University of Montreal and a letter of intent from the Quebec Ministry of Health and Social Services. - Launched the UpScript e-commerce telehealth platform to make it easier for MS patients to access PoNS Therapy. - Expanded the PoNSTEP outcome research trial, adding Montefiore Medical Center to the program. - In Canada, saw revenue growth with an exclusive distribution agreement and positive study results on TBI patients showing significant improvements in balance, gait, and work return rates.

Total revenue for the third quarter of 2023 was $143,000. Revenues in the U.S. decreased following the expiration of the PTAP program on June 30 as sales reverted to the cash-pay price. Revenues in Canada were $72,000 during the quarter, up 29% over the third quarter of last year.

• Expect our cash runway to extend into the second quarter of 2024.

• Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, as detailed in the Risk Factors section of recent filings with the SEC.

Q: How is the timeline for the Quebec Ministry of Health and Social Services to evaluate PoNS Therapy with 30 devices?

A: Their desire is to have all 30 patients either beginning treatment or lined up by the end of March of next year.

Q: Can you tell us the number of years of LTD claims for five individuals who returned to work?

A: Some averaged three and four years left on their LTD claims, some went as far as 20 years; the savings from these five patients were calculated as $1.6 million by Pacific Blue Cross